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systemic gram-negative bacterial infection.10
These observations, however, were far from
predictable because cells of hematopoietic
origin (eg, macrophages, dendritic cells) are
typically considered front-line sensors of
extracellular pathogens and are potent
mediators of TLR signals, with numerous
critical roles in regulating the interplay
between innate and adaptive immune
responses. Moreover, hematopoietic
progenitors express TLRs, which suggested
a potential direct mechanism of pathogen
sensing to activate emergency hematopoiesis.3
Evidence herein argues strongly in favor of
the importance of indirect sensing via the
endothelium for response to systemic
bacterial challenge.1,3
By contrast with systemic presentation,
a common route of bacterial infection is via
localized responses such as skin exposure or
inhalation. Because white blood cell counts
can increase in these conditions, localized
infection may trigger G-CSF and/or other
granulopoietic cytokine production by
endothelial and/or hematopoietic populations
to induce emergency granulopoiesis. One
hopes the results here will prompt further
investigation into cell populations and
mechanisms that regulate physiologically
relevant production of hematopoietic growth
factors in response to local and systemic
stressors (eg, infection, chemotherapy) as well
as the primary sources of these molecules in
steady state. Regardless, the fundamental idea
that the vasculature can sense and respond to
systemically delivered TLR agonists will no
doubt shape our view of how other potential
danger signals, such as extracellular nucleic
acids or cell damage molecules, might affect
hematopoiesis. Because these mediators are
released in numerous disease states, including
inﬂammation and cancer, and emergency
hematopoietic responses might in turn
inﬂuence disease outcomes (eg, production
of inﬂammatory or immunosuppressive
populations), understanding roles for
endothelial cell–derived hematopoietic
factors in different disease or pathogen-
elicited scenarios is of critical importance.
Both the vasculature and the marrow are
dispersed throughout the body, potentially
receiving not only systemically delivered
messages, but also local tweets that could
reveal important changes in environmental
conditions warranting emergency
hematopoietic responses. Our ability to
recognize and detect such signals is clearly
evident in healthy individuals in vivo. This
capacity needs to be correspondingly
enhanced in the laboratory to understand
the full spectrum of microbial messaging to
the marrow.
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Comment on Moorman et al, page 1434
The clinical path to
integrated genomics in ALL
-----------------------------------------------------------------------------------------------------
Jean-Pierre Bourquin UNIVERSITY CHILDREN’S HOSPITAL ZURICH
In this issue of Blood, Moorman et al show that most good-risk patients can
now be classiﬁed robustly by integrating the information from prevalent copy-
number alterations (CNAs) in relevant combinations and classical cytogenetic risk
factors in acute lymphoblastic leukemia (ALL).1
ALL is a complex genetic disease thatresults from the combination of lesions
in genes involved in the regulation of
hematopoiesis, lymphoid differentiation, cell
cycle, and proliferation. High-resolution
genetic proﬁling of ALL reveals an increasing
number of underlying mutations that modify
the function of transcription factors, epigenetic
regulators, or components of signaling
pathways, among others.2 For decades,
cytogeneticists have been aware of speciﬁc
chromosomal translocations, some of which
have been established as reliable risk factors
(see ﬁgure). However, these genetic risk factors
identify only some of the patients at risk.
Most study groups therefore also include
the assessment of minimal residual disease
(MRD) during induction chemotherapy for
risk stratiﬁcation, a powerful approach that
was pioneered by European study groups.3,4
The challenge is now to devise new approaches
to translate the rapidly expanding knowledge
of ALL genomics to the clinic in order
to deﬁne better prognostic markers and
speciﬁc druggable targets already at diagnosis.
The most common submicroscopic genetic
lesions include CNAs or sequence mutations
of hematopoietic transcription factors,
including PAX5, IKZF1, and EBF1; gene
rearrangements leading to overexpression of
the cytokine receptor component CRLF2;
mutations in JAK1 and JAK2 kinases; and
deletions of the CDKN2A/B loci encoding
the INK4/ARF tumor suppressor genes, to
name representative examples.2 Several of
these lesions have been associated with less
favorable outcome (such as CDKN2A/
CDKN2B and IKFZ1 deletions5,6 and
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P2RY8-CRLF2 fusion7), although a clear
consensus for their clinical application as
prognostic markers is lacking. Evidence
for prognostic signiﬁcance of recurrent
constellations of such genetic lesions has
emerged in the ﬁeld. One of the ﬁrst examples
for such a relevant combination is the strong
association of IKFZ1 deletions with BCR-
ABL1–positive ALL.8 Thus, the integration
of multiple parameters to identify recurrent
patterns may lead to better options for clinical
management.
In the present study,1 Moorman et al
took advantage of multiplex ligation-
dependent probe ampliﬁcation to detect the
most frequent CNAs retrospectively in.1600
patients treated in the ALL97/99 (n5 864)
and UKALL2003 (n5 742) trials in order
to establish constellations of CNAs that
would be associated with outcome. Using
ALL97/99 as a test cohort, they determined
the prognostic relevance of different CNA
combinations and integrated the resulting
3 CNA risk groups with 3 cytogenetic risk
groups to deﬁne 2 genetic risk groups. One
strength of the study was that the classiﬁcation
was then validated using an independent
cohort of patients treated in the UKALL2003
trial. Detection of CNA constellations that
were associated with good risk enabled the
reclassiﬁcation of half of the patients with
intermediate risk by cytogenetics into a group
with favorable outcome (see ﬁgure). In fact,
good-risk patients with low MRD after
induction chemotherapy had an overall
survival of 99%. The immediate potential of
this new approach for genetic classiﬁcation is
to identify favorable-risk patients who may
qualify for treatment de-escalation. This will
provide better tools for early interventions in
clinical trials in an attempt to reduce toxicity.
This study illustrates at a very practical
level the need for a systems-oriented analytical
approach to personalize ALL treatment. On
this path, we need to ingrate high-resolution
genetic proﬁling with all other available layers
of diagnostic and clinical information. For
example, a subset of patients in the genetic
good-risk group in this study remained
MRD positive, which was associated with
signiﬁcantly more relapses but still an overall
survival .90%, indicating that salvage was
possible in most cases. The drivers of this de
novo drug-resistance phenotype remain to be
discovered and limit the currently available
genetic classiﬁcation. Similarly, the relevant
genetic constellations of most high-risk
patients who do not carry a prognostic
cytogenetic marker (the so-called B-others)
need systematic exploration. Of obvious
importance among the B-other group is
BCR-ABL1–like leukemia with a gene
expression proﬁle that resembles BCR-ABL1
ALL.9 Next-generation sequencing of
representative cases revealed a wide range
of genetic alterations leading to activation
of cytokine-receptor and kinase signaling,
involving ABL1, ABL2, EPOR, IL7R,
JAK2, CSF1R, and PDGFRB, for example.10
Informative constellations also emerge here,
such as the association with IKFZ1 deletions,
CDKN2A/B deletions, or P2RY8-CRLF2
fusions in patientswithpoor risk based onMRD.
In conclusion, this study provides a widely
applicable strategy to improve the deﬁnition
of good-risk patients in ALL, which could
also be implemented in countries with more
limited access to high-end genomic technology.
It represents an important step toward
a more integrated use of biomedical data
to guide ALL therapy. We can expect the
rapid discovery of additional relevant ALL
molecular phenotypes and the translation
of this knowledge in interventional studies for
the beneﬁt of our patients.
Conﬂict-of-interest disclosure: The author
declares no competing ﬁnancial interests. n
REFERENCES
1. Moorman AV, Enshaei A, Schwab C, et al. A novel
integrated cytogenetic and genomic classiﬁcation reﬁnes
risk stratiﬁcation in pediatric acute lymphoblastic leukemia.
Blood. 2014;124(9):1434-1444.
2. Inaba H, Greaves M, Mullighan CG. Acute
lymphoblastic leukaemia. Lancet. 2013;381(9881):1943-1955.
3. Conter V, Bartram CR, Valsecchi MG, et al. Molecular
response to treatment redeﬁnes all prognostic factors in
children and adolescents with B-cell precursor acute
lymphoblastic leukemia: results in 3184 patients of the
AIEOP-BFM ALL 2000 study. Blood. 2010;115(16):
3206-3214.
4. Cave´ H, van der Werff ten Bosch J, Suciu S, et al;
European Organization for Research and Treatment of
Cancer–Childhood Leukemia Cooperative Group. Clinical
signiﬁcance of minimal residual disease in childhood acute
lymphoblastic leukemia. European Organization for
Research and Treatment of Cancer—Childhood Leukemia
Cooperative Group. N Engl J Med. 1998;339(9):591-598.
5. Mullighan CG, Su X, Zhang J, et al; Children’s
Oncology Group. Deletion of IKZF1 and prognosis in acute
lymphoblastic leukemia.N Engl J Med. 2009;360(5):470-480.
6. Do¨rge P, Meissner B, Zimmermann M, et al. IKZF1
deletion is an independent predictor of outcome in
pediatric acute lymphoblastic leukemia treated according to
the ALL-BFM 2000 protocol. Haematologica. 2013;98(3):
428-432.
7. Cario G, Zimmermann M, Romey R, et al. Presence
of the P2RY8-CRLF2 rearrangement is associated with
a poor prognosis in non-high-risk precursor B-cell acute
lymphoblastic leukemia in children treated according to the
ALL-BFM 2000 protocol. Blood. 2010;115(26):5393-5397.
8. Mullighan CG, Miller CB, Radtke I, et al. BCR-ABL1
lymphoblastic leukaemia is characterized by the deletion of
Ikaros. Nature. 2008;453(7191):110-114.
9. Den Boer ML, van Slegtenhorst M, De Menezes RX,
et al. A subtype of childhood acute lymphoblastic
leukaemia with poor treatment outcome: a genome-wide
classiﬁcation study. Lancet Oncol. 2009;10(2):125-134.
10. Roberts KG, Morin RD, Zhang J, et al. Genetic
alterations activating kinase and cytokine receptor signaling
in high-risk acute lymphoblastic leukemia. Cancer Cell.
2012;22(2):153-166.
© 2014 by The American Society of Hematology
Integration of cytogenetic risk groups and CNA profile information. CNAs are depicted as yellow boxes. The profiles are
ordered according to their associated risk (GR, good risk; IR, intermediate risk; PR, poor risk). For CNA data related to
this figure, see supplemental Table 3 in the article by Moorman et al, which begins on page 1434. Figure kindly provided
by A.V. Moorman, University of Newcastle.
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